Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Jaktinib for active ankylosing spondylitis (Phase II)
CTR20200937Phase 2Completed
- Sponsor
- Suzhou Zelgen Biopharmaceuticals
- Start
- Aug 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of jaktinib in ankylosing spondylitis (AS), sponsored by Suzhou Zelgen Biopharmaceuticals. Started Aug 2020; status: completed.
02
Drugs
jaktinib
03
Conditions
ankylosing spondylitis (AS)
Beyond the preview
Go deeper on CTR20200937.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200937.